Literature DB >> 11593059

Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance.

N Uchiyama-Kokubu1, T Watanabe.   

Abstract

The multidrug resistance (MDR) phenotype, either intrinsic and/or acquired, is discussed in relation to several MDR-associated markers such as P-glycoprotein (P-gp) encoded by mdr1, multidrug-resistance-associated protein (MRP) encoded by MRP and lung-resistance-associated protein (LRP) encoded by LRP. Well-characterized in vitro models are required to elucidate the mechanisms of MDR. The aim of the present study is the establishment of a drug-resistant subline from human colorectal adenocarcinoma HCT-15 that intrinsically expresses moderate levels of P-gp, MRP and LRP. Three adriamycin-resistant sublines (HCT-15/ADM1, HCT-15/ADM2 and HCT-15/ADM2-2) were established by stepwise exposure in growth medium that was supplemented with 25-200 ng/ml adriamycin-resulting in a 2.2- to 7.8-fold increase in IC(50) values by using the XTT assay. They were cross-resistant to MDR-related drugs, epirubicin, mitoxantrone, vincristine, etoposide and taxol, but not the MDR-unrelated drug, mytomycin C. The resistance to adriamycin was confirmed in vivo by a lack of sensitivity in athymic nude mice. Gene expression data for mdr1/P-gp, MRP/MRP and LRP/LRP on both mRNA and protein levels demonstrated that the molecules contributing to MDR in resistant sublines are mainly P-gp and partially MRP. The newly established adriamycin-resistant sublines of HCT-15 will provide clinically relevant tools to investigate how to overcome drug resistance and elucidate possible mechanisms of acquired MDR in human colon cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593059     DOI: 10.1097/00001813-200110000-00009

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  8 in total

1.  Antitumor effect of the paclitaxel-eluting membrane in a mouse model.

Authors:  Jin-Seok Park; Seok Jeong; Don Haeng Lee; Jin Hee Maeng; In Suh Park; Sangsoo Park
Journal:  Oncol Lett       Date:  2018-07-17       Impact factor: 2.967

2.  Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.

Authors:  Nisana Tepsiri; Liengchai Chaturat; Banchob Sripa; Wises Namwat; Sopit Wongkham; Vajarabhongsa Bhudhisawasdi; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

3.  Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo.

Authors:  Li-Zong Shen; Yi-Bing Hua; Xue-Ming Yu; Qing Xu; Tao Chen; Jian-Hua Wang; Wen-Xi Wu
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

4.  Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice.

Authors:  Bao-Jin Zhai; Ze-Yong Shao; Chun-Liang Zhao; Kai Hu; Feng Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

5.  Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil.

Authors:  Milica Pesić; Ana Podolski; Ljubisa Rakić; Sabera Ruzdijić
Journal:  Invest New Drugs       Date:  2009-06-18       Impact factor: 3.850

6.  Design, Synthesis and Structure-Activity Relationship Studies of Novel Survivin Inhibitors with Potent Anti-Proliferative Properties.

Authors:  Min Xiao; Jin Wang; Zongtao Lin; Yan Lu; Zhenmei Li; Stephen W White; Duane D Miller; Wei Li
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

7.  Anti-proliferative effect of Jesridonin on paclitaxel-resistant EC109 human esophageal carcinoma cells.

Authors:  Cong Wang; Liubin Guo; Saiqi Wang; Junwei Wang; Yongmei Li; Yinhui Dou; Ran Wang; Hongge Shi; Yu Ke; Hongmin Liu
Journal:  Int J Mol Med       Date:  2017-01-24       Impact factor: 4.101

8.  Leaf Extracts from Dillenia philippinensis Rolfe Exhibit Cytotoxic Activity to both Drug-Sensitive and Multidrug-Resistant Cancer Cells.

Authors:  Rachelle Anne S Dante; Regina Joyce E Ferrer; Sonia D Jacinto
Journal:  Asian Pac J Cancer Prev       Date:  2019-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.